Multiple myeloma and AL amyloid cardiomyopathy

Varayini Pankayatselvan; Inbar Raber; Alvin S. Chen; Bharath G. Rathakrishnan; Pablo A. Quintero; Marwa A. Sabe; Jason A. Freed; Arthur R. Garan

doi:10.5430/crim.v7n3p11

Case Reports in Internal Medicine ›› 2020, Vol. 7 ›› Issue (3) :11 -14. DOI: 10.5430/crim.v7n3p11

CASE REPORTS

research-article

Multiple myeloma and AL amyloid cardiomyopathy

Author information +

History +

PDF (417KB)

Abstract

AL amyloid cardiomyopathy is an increasingly recognized condition but arises less commonly with coexistent multiple myeloma. In this case report, we present a case of restrictive cardiomyopathy caused by AL amyloidosis and multiple myeloma, identified and treated using a multidisciplinary approach.

Keywords

Amyloidosis / Multiple myeloma / Restrictive cardiomyopathy / Heart failure

Cite this article

Download citation ▾

Varayini Pankayatselvan, Inbar Raber, Alvin S. Chen, Bharath G. Rathakrishnan, Pablo A. Quintero, Marwa A. Sabe, Jason A. Freed, Arthur R. Garan. Multiple myeloma and AL amyloid cardiomyopathy. Case Reports in Internal Medicine, 2020, 7(3): 11-14 DOI:10.5430/crim.v7n3p11

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Iadanza MG, Jackson MP, Hewitt EW, et al. A new era for understanding amyloid structures and disease. Nat Rev Mol Cell Biol. 2018; 19(12): 755-773. PMid:30237470. https://doi.org/10.1038/s41580-018-0060-8

[2]	Beel K, Vekemans MC, Bries G, et al. Diagnosis and treatment of AL Amyloidosis in 2015. Consensus guidelines of the Belgian Hematological Society. 2015; 6(5): 8.

[3]	Mussinelli R, Salinaro F, Alogna A, et al. Diagnostic and Prognostic Value of Low QRS Voltages in Cardiac AL Amyloidosis: Low QRS Voltages in Cardiac AL Amyloidosis. Ann Noninvasive Electrocardiol. 2013; 18(3): 271-280. PMid:23714086. https://doi.org/10.1111/anec.12036

[4]	Murtagh B, Hammill SC, Gertz MA, et al. Electrocardiographic findings in primary systemic amyloidosis and biopsy-proven cardiac involvement. Am J Cardiol. 2005; 95(4): 535-537. PMid:15695149. https://doi.org/10.1016/j.amjcard.2004.10.028

[5]	Liao R, Jain M, Teller P, et al. Infusion of Light Chains From Patients With Cardiac Amyloidosis Causes Diastolic Dysfunction in Isolated Mouse Hearts. Circulation. 2001; 104(14): 1594-1597. PMid:11581134. https://doi.org/10.1161/circ.104.14.1594

[6]	Feng D, Syed IS, Martinez M, et al. Intracardiac Thrombosis and Anticoagulation Therapy in Cardiac Amyloidosis. Circulation. 2009; 119(18): 2490-2497. PMid:19414641. https://doi.org/10.1161/CIRCULATIONAHA.108.785014

[7]	Comenzo RL, Reece D, Palladini G, et al. Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis. Leukemia. 2012; 26(11): 2317-2325. PMid:22475872. https://doi.org/10.1038/leu.2012.100

[8]	Comenzo RL, Zhou P, Fleisher M, et al. Seeking confidence in the diagnosis of systemic AL (Ig light-chain) amyloidosis: patients can have both monoclonal gammopathies and hereditary amyloid proteins. Blood. 2006; 107(9): 3489-3491. PMid:16439680. https://doi.org/10.1182/blood-2005-10-4148

[9]	Pardanani A, Thomas EW, Georgene S, et al. Circulating Peripheral Blood Plasma Cells as a Prognostic Indicator in Patients with Primary Systemic Amyloidosis. Blood 101, no. 3 (February 1, 2003): 827-30. PMid:12393530. https://doi.org/10.1182/blood-2002-06-1698

[10]	Falk RH, Alexander KM, Liao R, et al. AL (Light-Chain) Cardiac Amyloidosis: A Review of Diagnosis and Therapy. J Am Coll Cardiol. 2016; 68(12): 1323-1341. PMid:27634125. https://doi.org/10.1016/j.jacc.2016.06.053

[11]	Jimenez-Zepeda VH, Duggan P, Neri P, et al. Bortezomib-Containing Regimens for the Treatment of Newly Diagnosed and Relapsed Amyloid Light Chain Amyloidosis: A Single-Center Experience. Clin Lymphoma Myeloma Leuk. 2016; 16(6): e79-e84. PMid:27101985. https://doi.org/10.1016/j.clml.2016.03.005